Trade
Basic
Futures
Futures
Hundreds of contracts settled in USDT or BTC
TradFi
Gold
Trade global traditional assets with USDT in one place
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Participate in events to win generous rewards
Demo Trading
Use virtual funds to experience risk-free trading
Earn
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and enjoy airdrop rewards!
Futures Points
Earn futures points and claim airdrop rewards
Investment
Simple Earn
Earn interests with idle tokens
Auto-Invest
Auto-invest on a regular basis
Dual Investment
Buy low and sell high to take profits from price fluctuations
Soft Staking
Earn rewards with flexible staking
Crypto Loan
0 Fees
Pledge one crypto to borrow another
Lending Center
One-stop lending hub
VIP Wealth Hub
Customized wealth management empowers your assets growth
Private Wealth Management
Customized asset management to grow your digital assets
Quant Fund
Top asset management team helps you profit without hassle
Staking
Stake cryptos to earn in PoS products
Smart Leverage
New
No forced liquidation before maturity, worry-free leveraged gains
GUSD Minting
Use USDT/USDC to mint GUSD for treasury-level yields
More
AI pharmaceutical company Generate Biomedicines(GENB.US) IPO priced at $16 per share, listing on Nasdaq tonight
Generate Biomedicines (GENB.US), a company focused on AI drug development in immunology and oncology, officially announced its IPO offering price in the U.S. stock market. This biotech company, currently in Phase 3 clinical trials, issued 25 million shares at $16 each (midpoint of the $15 to $17 price range), successfully raising $400 million.
According to the company, its AI-driven Generate platform has built a tightly integrated “Design-Build-Test-Learn” closed-loop system aimed at generating proprietary data with therapeutic value and developing differentiated molecular solutions.
The company claims that its technological potential has been preliminarily validated, with three protein drugs developed through computational engineering entering human clinical trials. The fastest progressing, GB-0895, is an investigational long-acting monoclonal antibody targeting thymic stromal lymphopoietin, currently recruiting patients for a Phase 3 registration trial in severe asthma.
Generate Biomedicines plans to list on NASDAQ tonight under the ticker “GENB.” Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities, and Cantor Fitzgerald are joint bookrunners for this offering.